Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease Article Swipe
Michael G. Sugiyama
,
Haotian Cui
,
Dar’ya S. Redka
,
Mehran Karimzadeh
,
Edurne Rujas
,
Hassaan Maan
,
Sikander Hayat
,
Kyle Cheung
,
Rahul Misra
,
Joseph B. McPhee
,
Russell D. Viirre
,
Andrew Haller
,
Roberto J. Botelho
,
Raffi Karshafian
,
Sarah Sabatinos
,
Gregory D. Fairn
,
Seyed Ali Madani Tonekaboni
,
Andreas Windemuth
,
Jean‐Philippe Julien
,
Vijay Shahani
,
Stephen S. MacKinnon
,
Bo Wang
,
Costin N. Antonescu
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1101/2021.04.13.439274
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1101/2021.04.13.439274
The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cellbased experimental assessment reveals several clinically-relevant repurposing drug candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.
Related Topics
Concepts
Drug repositioning
Interactome
Drug
Repurposing
Coronavirus
In silico
Computational biology
Drug discovery
Coronavirus disease 2019 (COVID-19)
Disease
Drug development
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Drug target
Antiviral drug
Biology
Virology
Infectious disease (medical specialty)
Bioinformatics
Medicine
Pharmacology
Genetics
Gene
Pathology
Ecology
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1101/2021.04.13.439274
- https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdf
- OA Status
- green
- Cited By
- 6
- References
- 100
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3155672474
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3155672474Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1101/2021.04.13.439274Digital Object Identifier
- Title
-
Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus diseaseWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-04-13Full publication date if available
- Authors
-
Michael G. Sugiyama, Haotian Cui, Dar’ya S. Redka, Mehran Karimzadeh, Edurne Rujas, Hassaan Maan, Sikander Hayat, Kyle Cheung, Rahul Misra, Joseph B. McPhee, Russell D. Viirre, Andrew Haller, Roberto J. Botelho, Raffi Karshafian, Sarah Sabatinos, Gregory D. Fairn, Seyed Ali Madani Tonekaboni, Andreas Windemuth, Jean‐Philippe Julien, Vijay Shahani, Stephen S. MacKinnon, Bo Wang, Costin N. AntonescuList of authors in order
- Landing page
-
https://doi.org/10.1101/2021.04.13.439274Publisher landing page
- PDF URL
-
https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdfDirect OA link when available
- Concepts
-
Drug repositioning, Interactome, Drug, Repurposing, Coronavirus, In silico, Computational biology, Drug discovery, Coronavirus disease 2019 (COVID-19), Disease, Drug development, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Drug target, Antiviral drug, Biology, Virology, Infectious disease (medical specialty), Bioinformatics, Medicine, Pharmacology, Genetics, Gene, Pathology, EcologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
6Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 2, 2022: 2, 2021: 2Per-year citation counts (last 5 years)
- References (count)
-
100Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3155672474 |
|---|---|
| doi | https://doi.org/10.1101/2021.04.13.439274 |
| ids.doi | https://doi.org/10.1101/2021.04.13.439274 |
| ids.mag | 3155672474 |
| ids.openalex | https://openalex.org/W3155672474 |
| fwci | 0.96055272 |
| type | preprint |
| title | Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10211 |
| topics[0].field.id | https://openalex.org/fields/17 |
| topics[0].field.display_name | Computer Science |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1703 |
| topics[0].subfield.display_name | Computational Theory and Mathematics |
| topics[0].display_name | Computational Drug Discovery Methods |
| topics[1].id | https://openalex.org/T10887 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9976999759674072 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Bioinformatics and Genomic Networks |
| topics[2].id | https://openalex.org/T10118 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9934999942779541 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | SARS-CoV-2 and COVID-19 Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C103637391 |
| concepts[0].level | 3 |
| concepts[0].score | 0.941666841506958 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5308921 |
| concepts[0].display_name | Drug repositioning |
| concepts[1].id | https://openalex.org/C9760119 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8167369365692139 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q841382 |
| concepts[1].display_name | Interactome |
| concepts[2].id | https://openalex.org/C2780035454 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7100959420204163 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[2].display_name | Drug |
| concepts[3].id | https://openalex.org/C519536355 |
| concepts[3].level | 2 |
| concepts[3].score | 0.701772153377533 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q21021151 |
| concepts[3].display_name | Repurposing |
| concepts[4].id | https://openalex.org/C2777648638 |
| concepts[4].level | 5 |
| concepts[4].score | 0.6831520199775696 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q57751738 |
| concepts[4].display_name | Coronavirus |
| concepts[5].id | https://openalex.org/C2775905019 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6193113923072815 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q192572 |
| concepts[5].display_name | In silico |
| concepts[6].id | https://openalex.org/C70721500 |
| concepts[6].level | 1 |
| concepts[6].score | 0.6170318126678467 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[6].display_name | Computational biology |
| concepts[7].id | https://openalex.org/C74187038 |
| concepts[7].level | 2 |
| concepts[7].score | 0.6007139086723328 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1418791 |
| concepts[7].display_name | Drug discovery |
| concepts[8].id | https://openalex.org/C3008058167 |
| concepts[8].level | 4 |
| concepts[8].score | 0.5332908630371094 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[8].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[9].id | https://openalex.org/C2779134260 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4722316265106201 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[9].display_name | Disease |
| concepts[10].id | https://openalex.org/C64903051 |
| concepts[10].level | 3 |
| concepts[10].score | 0.45246952772140503 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2198549 |
| concepts[10].display_name | Drug development |
| concepts[11].id | https://openalex.org/C3007834351 |
| concepts[11].level | 5 |
| concepts[11].score | 0.44320523738861084 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q82069695 |
| concepts[11].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| concepts[12].id | https://openalex.org/C2989108626 |
| concepts[12].level | 2 |
| concepts[12].score | 0.43184298276901245 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q904407 |
| concepts[12].display_name | Drug target |
| concepts[13].id | https://openalex.org/C2779756493 |
| concepts[13].level | 3 |
| concepts[13].score | 0.43116265535354614 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q846227 |
| concepts[13].display_name | Antiviral drug |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.396066814661026 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| concepts[15].id | https://openalex.org/C159047783 |
| concepts[15].level | 1 |
| concepts[15].score | 0.36440086364746094 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[15].display_name | Virology |
| concepts[16].id | https://openalex.org/C524204448 |
| concepts[16].level | 3 |
| concepts[16].score | 0.3602760434150696 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[16].display_name | Infectious disease (medical specialty) |
| concepts[17].id | https://openalex.org/C60644358 |
| concepts[17].level | 1 |
| concepts[17].score | 0.33557644486427307 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q128570 |
| concepts[17].display_name | Bioinformatics |
| concepts[18].id | https://openalex.org/C71924100 |
| concepts[18].level | 0 |
| concepts[18].score | 0.3101452589035034 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[18].display_name | Medicine |
| concepts[19].id | https://openalex.org/C98274493 |
| concepts[19].level | 1 |
| concepts[19].score | 0.26343876123428345 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[19].display_name | Pharmacology |
| concepts[20].id | https://openalex.org/C54355233 |
| concepts[20].level | 1 |
| concepts[20].score | 0.0840495228767395 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[20].display_name | Genetics |
| concepts[21].id | https://openalex.org/C104317684 |
| concepts[21].level | 2 |
| concepts[21].score | 0.0822049081325531 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[21].display_name | Gene |
| concepts[22].id | https://openalex.org/C142724271 |
| concepts[22].level | 1 |
| concepts[22].score | 0.0 |
| concepts[22].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[22].display_name | Pathology |
| concepts[23].id | https://openalex.org/C18903297 |
| concepts[23].level | 1 |
| concepts[23].score | 0.0 |
| concepts[23].wikidata | https://www.wikidata.org/wiki/Q7150 |
| concepts[23].display_name | Ecology |
| keywords[0].id | https://openalex.org/keywords/drug-repositioning |
| keywords[0].score | 0.941666841506958 |
| keywords[0].display_name | Drug repositioning |
| keywords[1].id | https://openalex.org/keywords/interactome |
| keywords[1].score | 0.8167369365692139 |
| keywords[1].display_name | Interactome |
| keywords[2].id | https://openalex.org/keywords/drug |
| keywords[2].score | 0.7100959420204163 |
| keywords[2].display_name | Drug |
| keywords[3].id | https://openalex.org/keywords/repurposing |
| keywords[3].score | 0.701772153377533 |
| keywords[3].display_name | Repurposing |
| keywords[4].id | https://openalex.org/keywords/coronavirus |
| keywords[4].score | 0.6831520199775696 |
| keywords[4].display_name | Coronavirus |
| keywords[5].id | https://openalex.org/keywords/in-silico |
| keywords[5].score | 0.6193113923072815 |
| keywords[5].display_name | In silico |
| keywords[6].id | https://openalex.org/keywords/computational-biology |
| keywords[6].score | 0.6170318126678467 |
| keywords[6].display_name | Computational biology |
| keywords[7].id | https://openalex.org/keywords/drug-discovery |
| keywords[7].score | 0.6007139086723328 |
| keywords[7].display_name | Drug discovery |
| keywords[8].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[8].score | 0.5332908630371094 |
| keywords[8].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[9].id | https://openalex.org/keywords/disease |
| keywords[9].score | 0.4722316265106201 |
| keywords[9].display_name | Disease |
| keywords[10].id | https://openalex.org/keywords/drug-development |
| keywords[10].score | 0.45246952772140503 |
| keywords[10].display_name | Drug development |
| keywords[11].id | https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2 |
| keywords[11].score | 0.44320523738861084 |
| keywords[11].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| keywords[12].id | https://openalex.org/keywords/drug-target |
| keywords[12].score | 0.43184298276901245 |
| keywords[12].display_name | Drug target |
| keywords[13].id | https://openalex.org/keywords/antiviral-drug |
| keywords[13].score | 0.43116265535354614 |
| keywords[13].display_name | Antiviral drug |
| keywords[14].id | https://openalex.org/keywords/biology |
| keywords[14].score | 0.396066814661026 |
| keywords[14].display_name | Biology |
| keywords[15].id | https://openalex.org/keywords/virology |
| keywords[15].score | 0.36440086364746094 |
| keywords[15].display_name | Virology |
| keywords[16].id | https://openalex.org/keywords/infectious-disease |
| keywords[16].score | 0.3602760434150696 |
| keywords[16].display_name | Infectious disease (medical specialty) |
| keywords[17].id | https://openalex.org/keywords/bioinformatics |
| keywords[17].score | 0.33557644486427307 |
| keywords[17].display_name | Bioinformatics |
| keywords[18].id | https://openalex.org/keywords/medicine |
| keywords[18].score | 0.3101452589035034 |
| keywords[18].display_name | Medicine |
| keywords[19].id | https://openalex.org/keywords/pharmacology |
| keywords[19].score | 0.26343876123428345 |
| keywords[19].display_name | Pharmacology |
| keywords[20].id | https://openalex.org/keywords/genetics |
| keywords[20].score | 0.0840495228767395 |
| keywords[20].display_name | Genetics |
| keywords[21].id | https://openalex.org/keywords/gene |
| keywords[21].score | 0.0822049081325531 |
| keywords[21].display_name | Gene |
| language | en |
| locations[0].id | doi:10.1101/2021.04.13.439274 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402567 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| locations[0].source.host_organization | https://openalex.org/I2750212522 |
| locations[0].source.host_organization_name | Cold Spring Harbor Laboratory |
| locations[0].source.host_organization_lineage | https://openalex.org/I2750212522 |
| locations[0].license | |
| locations[0].pdf_url | https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1101/2021.04.13.439274 |
| locations[1].id | pmh:oai:digital.csic.es:10261/239325 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306400616 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DIGITAL.CSIC (Spanish National Research Council (CSIC)) |
| locations[1].source.host_organization | https://openalex.org/I134820265 |
| locations[1].source.host_organization_name | Consejo Superior de Investigaciones Científicas |
| locations[1].source.host_organization_lineage | https://openalex.org/I134820265 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | preprint |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | http://hdl.handle.net/10261/239325 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5065360311 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-8511-4204 |
| authorships[0].author.display_name | Michael G. Sugiyama |
| authorships[0].countries | CA |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada |
| authorships[0].institutions[0].id | https://openalex.org/I530967 |
| authorships[0].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[0].institutions[0].country_code | CA |
| authorships[0].institutions[0].display_name | Toronto Metropolitan University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Michael G. Sugiyama |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada |
| authorships[1].author.id | https://openalex.org/A5081166809 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-8119-9485 |
| authorships[1].author.display_name | Haotian Cui |
| authorships[1].countries | CA |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Computer Science, University of Toronto, Toronto, ON Canada |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210127509 |
| authorships[1].affiliations[1].raw_affiliation_string | Vector Institute, Toronto, ON, Canada |
| authorships[1].institutions[0].id | https://openalex.org/I185261750 |
| authorships[1].institutions[0].ror | https://ror.org/03dbr7087 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I185261750 |
| authorships[1].institutions[0].country_code | CA |
| authorships[1].institutions[0].display_name | University of Toronto |
| authorships[1].institutions[1].id | https://openalex.org/I4210127509 |
| authorships[1].institutions[1].ror | https://ror.org/03kqdja62 |
| authorships[1].institutions[1].type | facility |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210127509 |
| authorships[1].institutions[1].country_code | CA |
| authorships[1].institutions[1].display_name | Vector Institute |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Haotian Cui |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Computer Science, University of Toronto, Toronto, ON Canada, Vector Institute, Toronto, ON, Canada |
| authorships[2].author.id | https://openalex.org/A5090854893 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3996-1258 |
| authorships[2].author.display_name | Dar’ya S. Redka |
| authorships[2].affiliations[0].raw_affiliation_string | Cyclica Inc., Toronto, ON, Canada |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Dar’ya S. Redka |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Cyclica Inc., Toronto, ON, Canada |
| authorships[3].author.id | https://openalex.org/A5060815172 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7324-6074 |
| authorships[3].author.display_name | Mehran Karimzadeh |
| authorships[3].countries | CA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210127509 |
| authorships[3].affiliations[0].raw_affiliation_string | Vector Institute, Toronto, ON, Canada |
| authorships[3].institutions[0].id | https://openalex.org/I4210127509 |
| authorships[3].institutions[0].ror | https://ror.org/03kqdja62 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210127509 |
| authorships[3].institutions[0].country_code | CA |
| authorships[3].institutions[0].display_name | Vector Institute |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mehran Karimzadeh |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Vector Institute, Toronto, ON, Canada |
| authorships[4].author.id | https://openalex.org/A5044729940 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4465-5071 |
| authorships[4].author.display_name | Edurne Rujas |
| authorships[4].countries | CA, ES |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Biochemistry, University of Toronto, Toronto, ON, Canada |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I2801317318 |
| authorships[4].affiliations[1].raw_affiliation_string | Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I169108374, https://openalex.org/I4210118072 |
| authorships[4].affiliations[2].raw_affiliation_string | Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain |
| authorships[4].institutions[0].id | https://openalex.org/I2801317318 |
| authorships[4].institutions[0].ror | https://ror.org/057q4rt57 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2801317318 |
| authorships[4].institutions[0].country_code | CA |
| authorships[4].institutions[0].display_name | Hospital for Sick Children |
| authorships[4].institutions[1].id | https://openalex.org/I185261750 |
| authorships[4].institutions[1].ror | https://ror.org/03dbr7087 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I185261750 |
| authorships[4].institutions[1].country_code | CA |
| authorships[4].institutions[1].display_name | University of Toronto |
| authorships[4].institutions[2].id | https://openalex.org/I4210118072 |
| authorships[4].institutions[2].ror | https://ror.org/01pf2cj55 |
| authorships[4].institutions[2].type | facility |
| authorships[4].institutions[2].lineage | https://openalex.org/I134820265, https://openalex.org/I169108374, https://openalex.org/I4210118072 |
| authorships[4].institutions[2].country_code | ES |
| authorships[4].institutions[2].display_name | Instituto Biofisika |
| authorships[4].institutions[3].id | https://openalex.org/I169108374 |
| authorships[4].institutions[3].ror | https://ror.org/000xsnr85 |
| authorships[4].institutions[3].type | education |
| authorships[4].institutions[3].lineage | https://openalex.org/I169108374 |
| authorships[4].institutions[3].country_code | ES |
| authorships[4].institutions[3].display_name | University of the Basque Country |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Edurne Rujas |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain, Department of Biochemistry, University of Toronto, Toronto, ON, Canada, Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada |
| authorships[5].author.id | https://openalex.org/A5010534603 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3830-7177 |
| authorships[5].author.display_name | Hassaan Maan |
| authorships[5].countries | CA |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Medical Biophysics, University of Toronto, ON, Canada |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I4210127509 |
| authorships[5].affiliations[1].raw_affiliation_string | Vector Institute, Toronto, ON, Canada |
| authorships[5].institutions[0].id | https://openalex.org/I185261750 |
| authorships[5].institutions[0].ror | https://ror.org/03dbr7087 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I185261750 |
| authorships[5].institutions[0].country_code | CA |
| authorships[5].institutions[0].display_name | University of Toronto |
| authorships[5].institutions[1].id | https://openalex.org/I4210127509 |
| authorships[5].institutions[1].ror | https://ror.org/03kqdja62 |
| authorships[5].institutions[1].type | facility |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210127509 |
| authorships[5].institutions[1].country_code | CA |
| authorships[5].institutions[1].display_name | Vector Institute |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Hassaan Maan |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Medical Biophysics, University of Toronto, ON, Canada, Vector Institute, Toronto, ON, Canada |
| authorships[6].author.id | https://openalex.org/A5041018040 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5919-8371 |
| authorships[6].author.display_name | Sikander Hayat |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I150569930 |
| authorships[6].affiliations[0].raw_affiliation_string | Precision Cardiology Laboratory, Bayer US LLC, Cambridge, MA, USA |
| authorships[6].institutions[0].id | https://openalex.org/I150569930 |
| authorships[6].institutions[0].ror | https://ror.org/034ffbg36 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I150569930, https://openalex.org/I67348948 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Bayer (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Sikander Hayat |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Precision Cardiology Laboratory, Bayer US LLC, Cambridge, MA, USA |
| authorships[7].author.id | https://openalex.org/A5013276518 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Kyle Cheung |
| authorships[7].countries | CA |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[7].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[7].institutions[0].id | https://openalex.org/I530967 |
| authorships[7].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[7].institutions[0].country_code | CA |
| authorships[7].institutions[0].display_name | Toronto Metropolitan University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kyle Cheung |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[8].author.id | https://openalex.org/A5088997508 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-9573-2778 |
| authorships[8].author.display_name | Rahul Misra |
| authorships[8].countries | CA |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada |
| authorships[8].institutions[0].id | https://openalex.org/I530967 |
| authorships[8].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[8].institutions[0].country_code | CA |
| authorships[8].institutions[0].display_name | Toronto Metropolitan University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Rahul Misra |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada |
| authorships[9].author.id | https://openalex.org/A5038654542 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-6844-755X |
| authorships[9].author.display_name | Joseph B. McPhee |
| authorships[9].countries | CA |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[9].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[9].institutions[0].id | https://openalex.org/I530967 |
| authorships[9].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[9].institutions[0].country_code | CA |
| authorships[9].institutions[0].display_name | Toronto Metropolitan University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Joseph B. McPhee |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[10].author.id | https://openalex.org/A5080683741 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-7349-2822 |
| authorships[10].author.display_name | Russell D. Viirre |
| authorships[10].countries | CA |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[10].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[10].institutions[0].id | https://openalex.org/I530967 |
| authorships[10].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[10].institutions[0].country_code | CA |
| authorships[10].institutions[0].display_name | Toronto Metropolitan University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Russell D. Viirre |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[11].author.id | https://openalex.org/A5067731457 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Andrew Haller |
| authorships[11].countries | CA |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada |
| authorships[11].affiliations[1].raw_affiliation_string | Phoenox Pharma, Toronto, ON, Canada |
| authorships[11].institutions[0].id | https://openalex.org/I185261750 |
| authorships[11].institutions[0].ror | https://ror.org/03dbr7087 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I185261750 |
| authorships[11].institutions[0].country_code | CA |
| authorships[11].institutions[0].display_name | University of Toronto |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Andrew Haller |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, Phoenox Pharma, Toronto, ON, Canada |
| authorships[12].author.id | https://openalex.org/A5001790036 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-7820-0999 |
| authorships[12].author.display_name | Roberto J. Botelho |
| authorships[12].countries | CA |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[12].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[12].institutions[0].id | https://openalex.org/I530967 |
| authorships[12].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[12].institutions[0].country_code | CA |
| authorships[12].institutions[0].display_name | Toronto Metropolitan University |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Roberto J. Botelho |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[13].author.id | https://openalex.org/A5045266533 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-9589-9041 |
| authorships[13].author.display_name | Raffi Karshafian |
| authorships[13].countries | CA |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I1297363086 |
| authorships[13].affiliations[0].raw_affiliation_string | Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| authorships[13].affiliations[1].institution_ids | https://openalex.org/I530967 |
| authorships[13].affiliations[1].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[13].institutions[0].id | https://openalex.org/I1297363086 |
| authorships[13].institutions[0].ror | https://ror.org/04skqfp25 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I1297363086, https://openalex.org/I4399598460 |
| authorships[13].institutions[0].country_code | CA |
| authorships[13].institutions[0].display_name | St. Michael's Hospital |
| authorships[13].institutions[1].id | https://openalex.org/I530967 |
| authorships[13].institutions[1].ror | https://ror.org/05g13zd79 |
| authorships[13].institutions[1].type | education |
| authorships[13].institutions[1].lineage | https://openalex.org/I530967 |
| authorships[13].institutions[1].country_code | CA |
| authorships[13].institutions[1].display_name | Toronto Metropolitan University |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Raffi Karshafian |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| authorships[14].author.id | https://openalex.org/A5066843442 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-0685-7668 |
| authorships[14].author.display_name | Sarah Sabatinos |
| authorships[14].countries | CA |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[14].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[14].institutions[0].id | https://openalex.org/I530967 |
| authorships[14].institutions[0].ror | https://ror.org/05g13zd79 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I530967 |
| authorships[14].institutions[0].country_code | CA |
| authorships[14].institutions[0].display_name | Toronto Metropolitan University |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Sarah A. Sabatinos |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[15].author.id | https://openalex.org/A5052508191 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-6508-168X |
| authorships[15].author.display_name | Gregory D. Fairn |
| authorships[15].countries | CA |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[15].affiliations[0].raw_affiliation_string | Department of Biochemistry, University of Toronto, Toronto, ON, Canada |
| authorships[15].affiliations[1].institution_ids | https://openalex.org/I1297363086 |
| authorships[15].affiliations[1].raw_affiliation_string | Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| authorships[15].institutions[0].id | https://openalex.org/I1297363086 |
| authorships[15].institutions[0].ror | https://ror.org/04skqfp25 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I1297363086, https://openalex.org/I4399598460 |
| authorships[15].institutions[0].country_code | CA |
| authorships[15].institutions[0].display_name | St. Michael's Hospital |
| authorships[15].institutions[1].id | https://openalex.org/I185261750 |
| authorships[15].institutions[1].ror | https://ror.org/03dbr7087 |
| authorships[15].institutions[1].type | education |
| authorships[15].institutions[1].lineage | https://openalex.org/I185261750 |
| authorships[15].institutions[1].country_code | CA |
| authorships[15].institutions[1].display_name | University of Toronto |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Gregory D. Fairn |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Department of Biochemistry, University of Toronto, Toronto, ON, Canada, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| authorships[16].author.id | https://openalex.org/A5011534913 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Seyed Ali Madani Tonekaboni |
| authorships[16].affiliations[0].raw_affiliation_string | Cyclica Inc., Toronto, ON, Canada |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Seyed Ali Madani Tonekaboni |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Cyclica Inc., Toronto, ON, Canada |
| authorships[17].author.id | https://openalex.org/A5011665580 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-6985-9919 |
| authorships[17].author.display_name | Andreas Windemuth |
| authorships[17].affiliations[0].raw_affiliation_string | Cyclica Inc., Toronto, ON, Canada |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Andreas Windemuth |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Cyclica Inc., Toronto, ON, Canada |
| authorships[18].author.id | https://openalex.org/A5053782031 |
| authorships[18].author.orcid | https://orcid.org/0000-0001-7602-3995 |
| authorships[18].author.display_name | Jean‐Philippe Julien |
| authorships[18].countries | CA |
| authorships[18].affiliations[0].raw_affiliation_string | Department of Immunology, Toronto, ON, Canada |
| authorships[18].affiliations[1].institution_ids | https://openalex.org/I2801317318 |
| authorships[18].affiliations[1].raw_affiliation_string | Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada |
| authorships[18].affiliations[2].institution_ids | https://openalex.org/I185261750 |
| authorships[18].affiliations[2].raw_affiliation_string | Department of Biochemistry, University of Toronto, Toronto, ON, Canada |
| authorships[18].institutions[0].id | https://openalex.org/I2801317318 |
| authorships[18].institutions[0].ror | https://ror.org/057q4rt57 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I2801317318 |
| authorships[18].institutions[0].country_code | CA |
| authorships[18].institutions[0].display_name | Hospital for Sick Children |
| authorships[18].institutions[1].id | https://openalex.org/I185261750 |
| authorships[18].institutions[1].ror | https://ror.org/03dbr7087 |
| authorships[18].institutions[1].type | education |
| authorships[18].institutions[1].lineage | https://openalex.org/I185261750 |
| authorships[18].institutions[1].country_code | CA |
| authorships[18].institutions[1].display_name | University of Toronto |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Jean-Philippe Julien |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Department of Biochemistry, University of Toronto, Toronto, ON, Canada, Department of Immunology, Toronto, ON, Canada, Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada |
| authorships[19].author.id | https://openalex.org/A5064200481 |
| authorships[19].author.orcid | |
| authorships[19].author.display_name | Vijay Shahani |
| authorships[19].affiliations[0].raw_affiliation_string | Cyclica Inc., Toronto, ON, Canada |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Vijay Shahani |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Cyclica Inc., Toronto, ON, Canada |
| authorships[20].author.id | https://openalex.org/A5005004900 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-4117-0340 |
| authorships[20].author.display_name | Stephen S. MacKinnon |
| authorships[20].affiliations[0].raw_affiliation_string | Cyclica Inc., Toronto, ON, Canada |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Stephen S. MacKinnon |
| authorships[20].is_corresponding | True |
| authorships[20].raw_affiliation_strings | Cyclica Inc., Toronto, ON, Canada |
| authorships[21].author.id | https://openalex.org/A5100408160 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-9620-3413 |
| authorships[21].author.display_name | Bo Wang |
| authorships[21].countries | CA |
| authorships[21].affiliations[0].raw_affiliation_string | Peter Munk Cardiac Centre, University Health Centre, Toronto, ON, Canada |
| authorships[21].affiliations[1].institution_ids | https://openalex.org/I4210127509 |
| authorships[21].affiliations[1].raw_affiliation_string | Vector Institute, Toronto, ON, Canada |
| authorships[21].affiliations[2].institution_ids | https://openalex.org/I185261750 |
| authorships[21].affiliations[2].raw_affiliation_string | Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada |
| authorships[21].institutions[0].id | https://openalex.org/I185261750 |
| authorships[21].institutions[0].ror | https://ror.org/03dbr7087 |
| authorships[21].institutions[0].type | education |
| authorships[21].institutions[0].lineage | https://openalex.org/I185261750 |
| authorships[21].institutions[0].country_code | CA |
| authorships[21].institutions[0].display_name | University of Toronto |
| authorships[21].institutions[1].id | https://openalex.org/I4210127509 |
| authorships[21].institutions[1].ror | https://ror.org/03kqdja62 |
| authorships[21].institutions[1].type | facility |
| authorships[21].institutions[1].lineage | https://openalex.org/I4210127509 |
| authorships[21].institutions[1].country_code | CA |
| authorships[21].institutions[1].display_name | Vector Institute |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Bo Wang |
| authorships[21].is_corresponding | True |
| authorships[21].raw_affiliation_strings | Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada, Peter Munk Cardiac Centre, University Health Centre, Toronto, ON, Canada, Vector Institute, Toronto, ON, Canada |
| authorships[22].author.id | https://openalex.org/A5043066347 |
| authorships[22].author.orcid | https://orcid.org/0000-0001-9192-6340 |
| authorships[22].author.display_name | Costin N. Antonescu |
| authorships[22].countries | CA |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I530967 |
| authorships[22].affiliations[0].raw_affiliation_string | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada |
| authorships[22].affiliations[1].institution_ids | https://openalex.org/I1297363086 |
| authorships[22].affiliations[1].raw_affiliation_string | Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| authorships[22].institutions[0].id | https://openalex.org/I1297363086 |
| authorships[22].institutions[0].ror | https://ror.org/04skqfp25 |
| authorships[22].institutions[0].type | healthcare |
| authorships[22].institutions[0].lineage | https://openalex.org/I1297363086, https://openalex.org/I4399598460 |
| authorships[22].institutions[0].country_code | CA |
| authorships[22].institutions[0].display_name | St. Michael's Hospital |
| authorships[22].institutions[1].id | https://openalex.org/I530967 |
| authorships[22].institutions[1].ror | https://ror.org/05g13zd79 |
| authorships[22].institutions[1].type | education |
| authorships[22].institutions[1].lineage | https://openalex.org/I530967 |
| authorships[22].institutions[1].country_code | CA |
| authorships[22].institutions[1].display_name | Toronto Metropolitan University |
| authorships[22].author_position | last |
| authorships[22].raw_author_name | Costin N. Antonescu |
| authorships[22].is_corresponding | True |
| authorships[22].raw_affiliation_strings | Graduate Program in Molecular Science, Ryerson University, Toronto, ON, Canada, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-23T05:10:03.516525 |
| primary_topic.id | https://openalex.org/T10211 |
| primary_topic.field.id | https://openalex.org/fields/17 |
| primary_topic.field.display_name | Computer Science |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1703 |
| primary_topic.subfield.display_name | Computational Theory and Mathematics |
| primary_topic.display_name | Computational Drug Discovery Methods |
| related_works | https://openalex.org/W2899096130, https://openalex.org/W3190782215, https://openalex.org/W2902729297, https://openalex.org/W3110500039, https://openalex.org/W4255531208, https://openalex.org/W4396858017, https://openalex.org/W4400165188, https://openalex.org/W4206422705, https://openalex.org/W4320009247, https://openalex.org/W3186872001 |
| cited_by_count | 6 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2022 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2021 |
| counts_by_year[2].cited_by_count | 2 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1101/2021.04.13.439274 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402567 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| best_oa_location.source.host_organization | https://openalex.org/I2750212522 |
| best_oa_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1101/2021.04.13.439274 |
| primary_location.id | doi:10.1101/2021.04.13.439274 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402567 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| primary_location.source.host_organization | https://openalex.org/I2750212522 |
| primary_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| primary_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| primary_location.license | |
| primary_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2021/04/13/2021.04.13.439274.full.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1101/2021.04.13.439274 |
| publication_date | 2021-04-13 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W3008443627, https://openalex.org/W2766931063, https://openalex.org/W2470646526, https://openalex.org/W2153522302, https://openalex.org/W3045941675, https://openalex.org/W3127941442, https://openalex.org/W3138447431, https://openalex.org/W2143901293, https://openalex.org/W3010126769, https://openalex.org/W3086712138, https://openalex.org/W3009912996, https://openalex.org/W2027518730, https://openalex.org/W2912436263, https://openalex.org/W3094419073, https://openalex.org/W3093867667, https://openalex.org/W3121790907, https://openalex.org/W2054331966, https://openalex.org/W1990985479, https://openalex.org/W3047439400, https://openalex.org/W3096712778, https://openalex.org/W2244208996, https://openalex.org/W2113927019, https://openalex.org/W3022285953, https://openalex.org/W3093213262, https://openalex.org/W3111836713, https://openalex.org/W3110976643, https://openalex.org/W2123188122, https://openalex.org/W2093313266, https://openalex.org/W2770849724, https://openalex.org/W3085413554, https://openalex.org/W2959798450, https://openalex.org/W3120392574, https://openalex.org/W2604314403, https://openalex.org/W3089433758, https://openalex.org/W2913265314, https://openalex.org/W2339824543, https://openalex.org/W2170259414, https://openalex.org/W3093371139, https://openalex.org/W3080981445, https://openalex.org/W3033962184, https://openalex.org/W2893229904, https://openalex.org/W2461967493, https://openalex.org/W2114347295, https://openalex.org/W2082996493, https://openalex.org/W2775690235, https://openalex.org/W3016633510, https://openalex.org/W2973039076, https://openalex.org/W3035897035, https://openalex.org/W2909285126, https://openalex.org/W3047640609, https://openalex.org/W3129499416, https://openalex.org/W3110202162, https://openalex.org/W3159015105, https://openalex.org/W2609357089, https://openalex.org/W2141040025, https://openalex.org/W3034223907, https://openalex.org/W2087098495, https://openalex.org/W2117317247, https://openalex.org/W2029473819, https://openalex.org/W3015134137, https://openalex.org/W3125838829, https://openalex.org/W3124454689, https://openalex.org/W3130191864, https://openalex.org/W2767891136, https://openalex.org/W2103017472, https://openalex.org/W2604527271, https://openalex.org/W2950595506, https://openalex.org/W2917858269, https://openalex.org/W2056782561, https://openalex.org/W2067305633, https://openalex.org/W1994803330, https://openalex.org/W2009019945, https://openalex.org/W2081375228, https://openalex.org/W2130687290, https://openalex.org/W2962756421, https://openalex.org/W2977707586, https://openalex.org/W6767375087, https://openalex.org/W2294516783, https://openalex.org/W2130479394, https://openalex.org/W4234714728, https://openalex.org/W3033862284, https://openalex.org/W2170146596, https://openalex.org/W3210989748, https://openalex.org/W2586637063, https://openalex.org/W2099540110, https://openalex.org/W2600432485, https://openalex.org/W2122612816, https://openalex.org/W1970338528, https://openalex.org/W2770110160, https://openalex.org/W2108244474, https://openalex.org/W2550293637, https://openalex.org/W2171419407, https://openalex.org/W2970885858, https://openalex.org/W3132541973, https://openalex.org/W2964015378, https://openalex.org/W145587106, https://openalex.org/W3137864305, https://openalex.org/W2558217333, https://openalex.org/W2768244177, https://openalex.org/W3212420439 |
| referenced_works_count | 100 |
| abstract_inverted_index.a | 41, 122 |
| abstract_inverted_index.In | 103 |
| abstract_inverted_index.We | 39 |
| abstract_inverted_index.an | 7 |
| abstract_inverted_index.as | 111, 125, 127, 135 |
| abstract_inverted_index.be | 20 |
| abstract_inverted_index.by | 32, 90 |
| abstract_inverted_index.in | 92, 121, 137 |
| abstract_inverted_index.is | 30, 62 |
| abstract_inverted_index.of | 13, 58 |
| abstract_inverted_index.on | 64 |
| abstract_inverted_index.to | 6, 23, 44, 76, 95 |
| abstract_inverted_index.we | 105 |
| abstract_inverted_index.MET | 108 |
| abstract_inverted_index.Our | 60 |
| abstract_inverted_index.The | 1 |
| abstract_inverted_index.and | 50, 69, 114 |
| abstract_inverted_index.can | 19, 143 |
| abstract_inverted_index.for | 10, 55, 130 |
| abstract_inverted_index.has | 4 |
| abstract_inverted_index.led | 5 |
| abstract_inverted_index.new | 14, 46 |
| abstract_inverted_index.the | 11, 35, 56, 91, 107 |
| abstract_inverted_index.cell | 132 |
| abstract_inverted_index.drug | 16, 48, 53, 78, 87, 146 |
| abstract_inverted_index.have | 96 |
| abstract_inverted_index.host | 131 |
| abstract_inverted_index.need | 9 |
| abstract_inverted_index.such | 134 |
| abstract_inverted_index.that | 18 |
| abstract_inverted_index.this | 27 |
| abstract_inverted_index.well | 126 |
| abstract_inverted_index.with | 26, 34 |
| abstract_inverted_index.(GCN) | 68 |
| abstract_inverted_index.based | 63 |
| abstract_inverted_index.broad | 115 |
| abstract_inverted_index.graph | 65 |
| abstract_inverted_index.human | 36, 100, 139 |
| abstract_inverted_index.novel | 128 |
| abstract_inverted_index.roles | 129 |
| abstract_inverted_index.treat | 24 |
| abstract_inverted_index.which | 142 |
| abstract_inverted_index.caused | 31 |
| abstract_inverted_index.having | 112 |
| abstract_inverted_index.inform | 144 |
| abstract_inverted_index.potent | 113 |
| abstract_inverted_index.silico | 93 |
| abstract_inverted_index.urgent | 8 |
| abstract_inverted_index.IRAK1/4 | 136 |
| abstract_inverted_index.against | 99, 118 |
| abstract_inverted_index.coupled | 75 |
| abstract_inverted_index.further | 145 |
| abstract_inverted_index.manner, | 124 |
| abstract_inverted_index.rapidly | 21 |
| abstract_inverted_index.reveals | 83 |
| abstract_inverted_index.several | 84, 119 |
| abstract_inverted_index.targets | 49 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.COVID-19 | 2, 29 |
| abstract_inverted_index.activity | 98, 117 |
| abstract_inverted_index.analyses | 94 |
| abstract_inverted_index.analysis | 74 |
| abstract_inverted_index.approach | 43, 61 |
| abstract_inverted_index.deployed | 22 |
| abstract_inverted_index.disease. | 28 |
| abstract_inverted_index.identify | 45, 106 |
| abstract_inverted_index.involves | 70 |
| abstract_inverted_index.networks | 67 |
| abstract_inverted_index.pandemic | 3 |
| abstract_inverted_index.patients | 25 |
| abstract_inverted_index.proteins | 133 |
| abstract_inverted_index.studies. | 148 |
| abstract_inverted_index.COVID-19. | 59 |
| abstract_inverted_index.Cellbased | 80 |
| abstract_inverted_index.antiviral | 15, 47, 97, 116 |
| abstract_inverted_index.compounds | 54 |
| abstract_inverted_index.developed | 40 |
| abstract_inverted_index.discovery | 147 |
| abstract_inverted_index.infection | 33 |
| abstract_inverted_index.inhibitor | 109 |
| abstract_inverted_index.predicted | 89 |
| abstract_inverted_index.repurpose | 51 |
| abstract_inverted_index.therapies | 17 |
| abstract_inverted_index.treatment | 57 |
| abstract_inverted_index.assessment | 82 |
| abstract_inverted_index.candidates | 88 |
| abstract_inverted_index.capmatinib | 110 |
| abstract_inverted_index.host-virus | 72 |
| abstract_inverted_index.infection, | 141 |
| abstract_inverted_index.infection. | 102 |
| abstract_inverted_index.multiscale | 71 |
| abstract_inverted_index.off-target | 77 |
| abstract_inverted_index.supporting | 138 |
| abstract_inverted_index.SARS-CoV-2. | 38 |
| abstract_inverted_index.coronavirus | 37, 101, 140 |
| abstract_inverted_index.interactome | 73 |
| abstract_inverted_index.particular, | 104 |
| abstract_inverted_index.repurposing | 86 |
| abstract_inverted_index.experimental | 81 |
| abstract_inverted_index.predictions. | 79 |
| abstract_inverted_index.computational | 42 |
| abstract_inverted_index.convolutional | 66 |
| abstract_inverted_index.coronaviruses | 120 |
| abstract_inverted_index.identification | 12 |
| abstract_inverted_index.MET-independent | 123 |
| abstract_inverted_index.clinically-relevant | 52, 85 |
| cited_by_percentile_year.max | 96 |
| cited_by_percentile_year.min | 93 |
| corresponding_author_ids | https://openalex.org/A5005004900, https://openalex.org/A5043066347, https://openalex.org/A5100408160 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 23 |
| corresponding_institution_ids | https://openalex.org/I1297363086, https://openalex.org/I185261750, https://openalex.org/I4210127509, https://openalex.org/I530967 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.78469792 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |